These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U, DUAL study group. Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798 [Abstract] [Full Text] [Related]
9. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888 [Abstract] [Full Text] [Related]
11. [Allergic march in children, from rhinitis to asthma: management, indication of immunotherapy]. Scheinmann P, Pham Thi N, Karila C, de Blic J. Arch Pediatr; 2012 Mar; 19(3):330-4. PubMed ID: 22306361 [Abstract] [Full Text] [Related]
14. Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life. Zeldin Y, Weiler Z, Magen E, Tiosano L, Kidon MI. Isr Med Assoc J; 2008 Dec; 10(12):869-72. PubMed ID: 19160945 [Abstract] [Full Text] [Related]